prolonged disease-free interval from the time of diagnosis until the development of distant metastases has also been linked to an improved survival. 4, 8, 9 Based on this observation, patients with STS and synchronous metastases should have a dismal prognosis.
A dif cult dilemma surrounds the management of this group of patients with STS who present with synchronous metastases. Although an improved survival has been demonstrated in patients with surgically resected metachronous metastases with STS, 10 ,11 similar information is not available for patients with STS and synchronous metastases. The purpose of this study was to describe the experience at a tertiary care cancer center, identify prognostic factors associated with improved survival, and to assess the impact of surgical intervention on their outcome.
Patients and methods
A retrospective review of the Roswell Park Cancer Institute (RPCI) Tumor Registry from 1971 to 1998 was performed to identify patients with the diagnosis of a soft tissue sarcoma and synchronous metastases. Sarcomas felt to be of bone origin were excluded from the review. Histological diagnosis of soft tissue sarcoma was performed or con rmed by RPCI pathologists. Fifty-three patients were identi ed as having a soft tissue sarcoma with synchronous metastases. Review of the medical records revealed ve patients who did not meet the de nition of synchronous metastases. Four patients had delayed development of metastatic disease and one patient had a synchronous second non-sarcomatous primary tumor. Consequently, the study group for this study consisted of 48 patients. The diagnosis of metastatic disease was established by biopsy of suspicious lesions or strongly suspected based on radiological studies and con rmed by subsequent progression of disease. For the purpose of this study, synchronous was de ned as either: (1) metastatic disease present at the time of pathological diagnosis of the primary tumor, or (2) metastatic disease present at the time of the rst surgical intervention for the primary tumor.
A complete review of the RPCI medical record and available outside information was performed for all patients identi ed from the Tumor Registry. Information obtained included: patient demographics (age, gender, race), presentation (symptoms, diagnosis, work-up), tumor characteristics (histology, size, location, metastatic sites), treatment (surgery, chemotherapy, radiation), follow-up, and survival.The study was approved by the Roswell Park Cancer Institute Institutional Review Board. Patient con dentiality was maintained.
Estimated overall survival was calculated by the method of Kaplan and Meier. Tests of signi cance with respect to survival distributions were based on the log-rank test. Statistical signi cance for all analyses was de ned as p < 0.05. All statistical calculations were performed using SPSS for Windows (ver. 6.1).
Results
Demographic information and tumor characteristics for the 48 patients are summarized in Table 1 . This study population includes a wide variety of histological subtypes.
The diagnosis of metastases was made pre-operatively in 40 patients (83%) and at the time of the rst surgery in eight patients (17%). Seventy-three percent of patients (n = 35) had metastases limited to one anatomic site at the time of diagnosis ( Table  2 ). Synchronous pulmonary metastases were most commonly encountered (n = 30). Nodal disease was found in 11 patients. Hepatic involvement was a rare event (n = 4).
Surgery played an integral role at our institution in the treatment of both the primary tumor and the metastatic disease. Forty-ve patients underwent at least one attempt at surgical resection of the primary tumor and two or more operations were performed on 13 patients. Seven patients had an unresectable primary tumor at the time of surgical intervention, three of which had concomitant sarcomatosis. Seventeen patients underwent at least one attempt at metastasectomy. Resection of pulmonary metastases was the most common procedure (n = 13) with four patients undergoing two or more operations ( Table  3 ). The median survival of patients who underwent at least one metastasectomy procedure was 16.0 versus 14 months for those with no attempt at resection of metastatic disease (Fig. 1 , p = 0.3).
Chemotherapy was given to 43 of 48 patients (90%), with 15 patients (31%) receiving three or more different chemotherapeutic regimens. The majority also received at least one regimen of doxorubicin based therapy (n = 40, 93%). Seven patients were treated with chemotherapy prior to any attempt at surgical resection of the primary tumor. Twentyeight percent of patients receiving chemotherapy (n = 12) were given at least one regimen through a nonintravenous route. Intra-arterial doxorubicin was administered into the extremity in seven patients, via the hepatic artery in three patients, and via the pulmonary artery in two patients. Cisplatin was given intraperitoneally to two patients and intrathoracically to one patient. Sixteen patients received radiation therapy to the primary tumor site.
The overall median survival was 15.0 months. At the time of last follow-up, 88% of the patients had died (n = 42).Three patients are alive with disease at 15, 9, and 6 months. An additional three patients are alive with no evidence of disease at 19, 8, and 8 months. Overall survival is presented in Fig. 2 . The effect of various factors on overall survival is shown in Table 4 . None of the examined variables had a statistically signi cant impact on overall survival.
Discussion
The development of metastases from STS carries a poor prognosis. With metastatic disease, 62-80% of patients will have pulmonary metastases and 50-70% will have isolated pulmonary metastases. 4, 8, 10, 12, 13 Lymph node metastases from STS are generally considered a rare event, present in only 2.6-16% of all patients with STS.
14,15 Approximately 1.2-6.6% of all patients with STS develop soft tissue metastases, usually as a late event associated with widely disseminated disease. 16 Median survival following the diagnosis of metastatic disease ranges from 8 to 14.5 months.
3,4,7,12 Two-year overall survival is 20-28%, decreasing to 10% for patients with multiple sites of metastatic disease. 3, 4, 12 Several prognostic factors for overall survival of patients with metastatic STS have been identi ed.Tumor size >10 cm, local recurrence, unresectable metastases, age >50 years, and a disease-free interval <1 year have all been associated with a decreased survival after the development of metastases. 4, 7, 8 The proportion of patients with STS who present with synchronous metastatic disease ranges from 12 to 23% in uncontrolled series and represents a subgroup of patients with no disease-free interval. 5 In the subgroup of patients with poorly differentiated tumors, >5cm, 20% had metastatic disease at presentation. Those patients who present with synchronous metastases represent a dif cult subgroup to manage. Our approach to this type of patient has been traditionally aggressive surgery for the primary and metastatic sites. This approach allows us to fully evaluate the role of surgery in these patients. The median overall survival in this series was 15.0 months with 21% of patients alive at 2 years. Ninety-four percent of patients had surgery at the site of the primary tumor and local control was eventually achieved in over one-half of all patients. Thirty-ve percent of patients underwent at least one attempted metastastectomy; 76% of these were for pulmonary metastases. Although the median survival for patients undergoing metastastectomy was slightly longer that of the patients deemed unresectable, the difference was not statistically signi cant.The bene t of pulmonary metastastectomy for STS in selected patients with metachronous metastases has a 3-year overall survival of 46-54%. 10, 11 Prognostic factors identi ed for extended survival following pulmonary metastastectomy include an extended disease-free interval and complete metastasectomy. 10, 11, 17 We did not observe an improved overall survival in those patients who underwent metastastectomy versus those deemed unresectable. Several factors may present dif culties in the interpretation of the data. The patient population included in this series was comprised of a small sample size identi ed over a 27-year period. During that period of time, medical technology has evolved. For example, computer tomography most assuredly permitted earlier diagnosis of pulmonary metastatic disease in 1998 as compared with 1971 when only chest X-ray was available. Additionally, analysis of several factors failed to identify any variable associated with improved overall survival. The uniform outcome of the patients in our study is most likely due to the fact that all patients had similar synchronous metastatic tumor burdens that nulli ed the predictive value of standard prognostic factors.
Given the disseminated nature of their disease, the majority of patients received systemic chemotherapy (90%), usually consisting of at least one doxorubicinbased regimen. The overall bene t of chemotherapy in the treatment of metastatic STS is somewhat controversial. Response rates have ranged from 15 to 48%, but there has been little impact on overall survival. 2, 18, 19 Approximately one-third of the patients was treated with three or more different chemotherapy regimens with no apparent impact on survival. It is conceivable the various chemotherapeutic regimens or radiation therapy had an impact on survival. However, given the diversity of regimens, the heterogeneous tumor histology present, variations in biological response to non-surgical therapy, and the small sample size, it is impossible to determine the presence of any effect.
Despite the fact that there is no disease-free interval, the survival of patients with STS and synchronous metastases is comparable to those who develop delayed metastatic disease. However, there does not appear to be any added survival bene t of metastastectomy for patients with STS and synchronous metastases as has been observed in metastastectomy for metachronous metastases. Although this is a small retrospective series of patients over a large period of time, the results appear to argue against the 
